Physician profile
Mark Gill Kosko
NPI 1447578752
$26,809.85
in general payments reported to CMS, 2019-2025
22 companies · $822 in 2025
The $822 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $190 · 2021: $799 · 2022: $951 · 2023: $1,102 · 2024: $712 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.25 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19,252.83 | 2019-2020 | |
| Alcon Vision LLC | $1,831.72 | 2019-2025 | Clareon, Rocklatan, Total30 |
| Allergan, INC. | $1,406.54 | 2019-2022 | |
| Ivantis, INC | $953.10 | 2019-2021 | |
| Abbvie INC. | $762.08 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $601.40 | 2019 | |
| Glaukos Corporation | $478.10 | 2021-2024 | Idose |
| Rxsight INC | $407.93 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $274.98 | 2022-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Ellexiscience | $146.61 | 2019 | |
| Bausch & Lomb Americas INC. | $143.51 | 2023-2025 | Miebo, Vyzulta |
| Amgen INC. | $130.25 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $82.38 | 2019 | |
| Biotissue Holdings INC. | $71.55 | 2022-2023 | |
| Horizon Therapeutics Plc | $64.20 | 2022-2023 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $54.36 | 2024 | |
| Mallinckrodt Hospital Products INC. | $42.23 | 2025 | Acthar |
| Thea Pharma INC. | $35.81 | 2024-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $26.40 | 2021-2022 | |
| Oyster Point Pharma, INC. | $23.45 | 2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 | |
| Iridex Corporation | $8.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kosko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.